Search
Prothena Corporation PLC
PRTAAdd to Watchlist
8.120USD
-0.290-3.45%
Close 07-31 16:00（ET）Quotes delayed by 15 min
425.11MMarket Cap
LossP/E TTM
More Details of Prothena Corporation PLC Company
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Prothena Corporation PLC Info
Ticker SymbolPRTA
Company nameProthena Corporation PLC
IPO dateDec 21, 2012
CEOKinney (Gene G)
Number of employees163
Security typeOrdinary Share
Fiscal year-endDec 21
Address77 Sir John Rogerson's Quay, Block C
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal codeD02 VK60
Phone35312362500
Websitehttps://www.prothena.com/
Ticker SymbolPRTA
IPO dateDec 21, 2012
CEOKinney (Gene G)
Company Executives of Prothena Corporation PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Mr. Tran B. Nguyen
Mr. Tran B. Nguyen
Chief Financial Officer, Chief Strategy Officer
Chief Financial Officer, Chief Strategy Officer
--
--
Dr. Gene G. Kinney, Ph.D.
Dr. Gene G. Kinney, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Karin L. Walker, CPA
Ms. Karin L. Walker, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Ms. Paula K. Cobb
Ms. Paula K. Cobb
Independent Director
Independent Director
--
--
Mr. Michael J. Malecek, J.D.
Mr. Michael J. Malecek, J.D.
Chief Legal Officer, Company Secretary
Chief Legal Officer, Company Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Mr. Tran B. Nguyen
Mr. Tran B. Nguyen
Chief Financial Officer, Chief Strategy Officer
Chief Financial Officer, Chief Strategy Officer
--
--
FAQs
Who are the top five shareholders of Prothena Corporation PLC?
The top five shareholders of Prothena Corporation PLC are: Mr. Brandon S. Smith
How many institutions hold shares of Prothena Corporation PLC (PRTA)?
As of 2026Q1, 436 institutions hold shares of Prothena Corporation PLC, with a combined market value of approximately 50.39M, accounting for 96.24% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -14521914.00.